SCHEMBL2724129

SCHEMBL2724129

CC(C)n1c(Nc2ccc(C(=O)Nc3ccccc3NC(=O)OC(C)(C)C)cc2)nc2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.52
BRD4 O60885 3/20 0.48
POLB P06746 1/20 0.47
ALDH1A1 P00352 1/20 0.47
KMT2A Q03164 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.45
GAA P10253 2/20 0.44
LMNA P02545 1/20 0.44
PDE11A Q9HCR9 1/20 0.44
PDE10A Q9Y233 1/20 0.44
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
NAMPT P43490 1/20 0.42
RPS6KA2 Q15349 5/20 0.42
RPS6KA3 P51812 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2724128 0.92 HSD17B10 (0.56) HSD17B10BRD4POLBALDH1A1KMT2A
SCHEMBL2725872 0.83 HSD17B10 (0.57) HSD17B10POLBALDH1A1KMT2AIRAK4
SCHEMBL18263887 0.79 HSD17B10 (0.67) HSD17B10POLBALDH1A1KMT2AIRAK4
SCHEMBL2725093 0.77 HSD17B10 (0.67) HSD17B10POLBALDH1A1KMT2AIRAK4
SCHEMBL9109386 0.77 HDAC6 (0.54) HSD17B10POLBALDH1A1KMT2APDE11A
SCHEMBL2724437 0.77 HSD17B10 (0.74) HSD17B10POLBALDH1A1KMT2AIRAK4
SCHEMBL24890579 0.74 NAMPT (0.57) ALDH1A1KMT2ALMNANPC1RAB9A
SCHEMBL248347 0.73 CACNA1B (0.57) ALDH1A1KMT2ANAMPT
SCHEMBL2829176 0.72 POLB (0.56) POLBALDH1A1KMT2ANPC1RAB9A
SCHEMBL30944753 0.72 F10 (0.48) ALDH1A1KMT2AGAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) 2020-03-17 US disclosed
US-20190084940-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2019-03-21 US disclosed
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 US disclosed
US-9464059-B2 Benzamide derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-10-11 US disclosed
US-20150284336-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2015-10-08 US disclosed
US-9125901-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2015-09-08 US disclosed
EP-2445345-B1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RES INST (US) 2014-08-27 EP disclosed
US-20120142922-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2012-06-07 US disclosed
EP-2445345-A1 BENZAMIDE DERIVATIVES The Translational Genomics Research Institute (US) 2012-05-02 EP disclosed
WO-2010151441-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof MCL1, BRDT, BOD1L1 HSD17B10 2881/4885BRD4 17/4885POLB 1663/4885
US-20120142922-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885BRD4 6/4885POLB 351/4885
US-20150284336-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885BRD4 6/4885POLB 351/4885
US-20160362382-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885BRD4 6/4885POLB 351/4885
US-20190084940-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885BRD4 6/4885POLB 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.